
## David N Juurlink

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2570982/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Receipt of Overactive Bladder Drugs and Incident Dementia: A Population-based Case-control Study. European Urology Focus, 2022, 8, 1433-1440.	3.1	5
2	Introduction to a series of <scp>P</scp> ro/ <scp>C</scp> on papers in <scp>C</scp> linical <scp>T</scp> oxicology. British Journal of Clinical Pharmacology, 2022, 88, 56-57.	2.4	0
3	Responding to the opioid crisis in North America and beyond: recommendations of the Stanford–Lancet Commission. Lancet, The, 2022, 399, 555-604.	13.7	180
4	Loperamide Cardiac Toxicity: Pathophysiology, Presentation, and Management. Canadian Journal of Cardiology, 2022, 38, 1378-1383.	1.7	6
5	Treating acetaminophen overdose. Cmaj, 2022, 194, E554-E554.	2.0	2
6	Prescribing Nirmatrelvir/Ritonavir for COVID-19 in Advanced CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 1247-1250.	4.5	36
7	Opioid use in pregnancy: An emerging health crisis. Obstetric Medicine, 2021, 14, 211-219.	1.1	8
8	Trends in Postpartum Opioid Prescribing: A Time Series Analysis. Clinical Pharmacology and Therapeutics, 2021, 110, 1004-1010.	4.7	3
9	Dental Opioid Prescription Characteristics and the Risk of New, Persistent Use. American Journal of Preventive Medicine, 2021, 60, 831-839.	3.0	9
10	Medical cannabis or cannabinoids for chronic pain: a clinical practice guideline. BMJ, The, 2021, 374, n2040.	6.0	54
11	Metronidazole-induced neurotoxicity. Cmaj, 2021, 193, E1630-E1630.	2.0	5
12	Ketamine for the treatment of acute pain. Cmaj, 2021, 193, E1663-E1663.	2.0	4
13	New Opioid Use and Risk of Emergency Department Visits Related to Motor Vehicle Collisions in Ontario, Canada. JAMA Network Open, 2021, 4, e2134248.	5.9	3
14	The impact of proposed regulatory changes and rescheduling on low-dose codeine purchasing in Canada: a time-series analysis. CMAJ Open, 2021, 9, E1181-E1186.	2.4	1
15	One-Year Mortality After Emergency Department Visit for Nonfatal Opioid Poisoning: A Population-Based Analysis. Annals of Emergency Medicine, 2020, 75, 20-28.	0.6	19
16	ACMT Position Statement: Caring for Patients with Opioid Use Disorder during Coronavirus Disease Pandemic. Journal of Medical Toxicology, 2020, 16, 484-486.	1.5	2
17	The Implausibility of Neonatal Opioid Toxicity from Breastfeeding. Clinical Pharmacology and Therapeutics, 2020, 108, 964-970.	4.7	22
18	Response to "understanding the behavioural determinants of opioid prescribing among family physicians: a qualitative study― BMC Family Practice, 2020, 21, 109.	2.9	0

#	Article	IF	CITATIONS
19	Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. Cmaj, 2020, 192, E450-E453.	2.0	175
20	Analysis of Trends in Insulin Utilization and Spending Across Canada From 2010 to 2015. Canadian Journal of Diabetes, 2019, 43, 179-185.e1.	0.8	11
21	Carfentanil: a narrative review of its pharmacology and public health concerns. Canadian Journal of Anaesthesia, 2019, 66, 414-421.	1.6	48
22	Prevention of Opioid Overdose. New England Journal of Medicine, 2019, 380, 2246-2255.	27.0	78
23	Response to "Opioids for chronic pain― Cmaj, 2019, 191, E565-E565.	2.0	0
24	Tramadol and the risk of seizure: nested case-control study of US patients with employer-sponsored health benefits. BMJ Open, 2019, 9, e026705.	1.9	16
25	Lofexidine for Opioid Withdrawal: Small Effects at an Exorbitant Price. Journal of Addiction Medicine, 2019, 13, 167-168.	2.6	6
26	Evaluation of the fentanyl patch-for-patch program in Ontario, Canada. International Journal of Drug Policy, 2019, 66, 82-86.	3.3	8
27	Predictive factors for sleep apnoea in patients on opioids for chronic pain. BMJ Open Respiratory Research, 2019, 6, e000523.	3.0	23
28	Individual opioids, and long- versus short-acting opioids, for chronic noncancer pain. Medicine (United States), 2019, 98, e17647.	1.0	3
29	Metformin Use and Kidney Cancer Survival Outcomes. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 275-284.	1.3	6
30	Extracorporeal treatment in salicylate poisoning. Clinical Toxicology, 2019, 57, 377-378.	1.9	1
31	Critiquing the CDC Opioid Guideline: Some Light From the Heat. Clinical Pharmacology and Therapeutics, 2018, 103, 966-968.	4.7	4
32	Argyria caused by chronic ingestion of silver. Cmaj, 2018, 190, E139-E139.	2.0	15
33	Catastrophic drug coverage: utilization insights from the Ontario Trillium Drug Program. CMAJ Open, 2018, 6, E132-E138.	2.4	4
34	The authors respond to "The 2017 Canadian opioid guideline: already time for an overhaul― Cmaj, 2018, 190, E301-E301.	2.0	3
35	Medication use and kidney cancer survival: A populationâ€based study. International Journal of Cancer, 2018, 142, 1776-1785.	5.1	9
36	Challenges Interpreting Chemoprevention Studies Using Observational Data. Journal of Clinical Oncology, 2018, 36, 628-629.	1.6	5

#	Article	IF	CITATIONS
37	High-strength opioid formulations: the case for a ministerial recall. Cmaj, 2018, 190, E1404-E1405.	2.0	7
38	Studying Drug Safety in the Real World. JAMA Internal Medicine, 2018, 178, 1533.	5.1	8
39	Association of Chronic Opioid Use With Presidential Voting Patterns in US Counties in 2016. JAMA Network Open, 2018, 1, e180450.	5.9	51
40	Publicly Funded Oral Chronic Hepatitis B Treatment Patterns in Ontario over 16 Years: An Ecologic Study. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 464-468.	0.9	2
41	Real-world health care utilization and effectiveness of omalizumab for the treatment of severe asthma. Annals of Allergy, Asthma and Immunology, 2018, 120, 59-65.e2.	1.0	18
42	Overdose Risk in Young Children of Women Prescribed Opioids. , 2018, , 40-44.		44
43	Self-Monitoring of Blood Glucose: Impact of Quantity Limits in Public Drug Formularies on Provincial Costs Across Canada. Canadian Journal of Diabetes, 2017, 41, 138-142.	0.8	3
44	Impact of pharmacist administration of influenza vaccines on uptake in Canada. Cmaj, 2017, 189, E146-E152.	2.0	71
45	Response to "Clarification from the College of Physicians and Surgeons of BC on commentary about limitations of the CDC guideline for prescribing opioids― Cmaj, 2017, 189, E509-E509.	2.0	2
46	Clinical Review: Loperamide Toxicity. Annals of Emergency Medicine, 2017, 70, 245-252.	0.6	73
47	Comment on Shively etÂal. "Acute salicylate poisoning: risk factors for severe outcome― Clinical Toxicology, 2017, 55, 609-609.	1.9	Ο
48	Opioid Overuse or NSAID Underuse? AÂResponse to the Pain Guide. American Journal of Kidney Diseases, 2017, 69, 865.	1.9	4
49	Statin use and kidney cancer survival outcomes: A systematic review and meta-analysis. Cancer Treatment Reviews, 2017, 52, 105-116.	7.7	53
50	Association between statin use and ischemic stroke or major hemorrhage in patients taking dabigatran for atrial fibrillation. Cmaj, 2017, 189, E4-E10.	2.0	41
51	Pregabalin and heart failure: <scp>A</scp> populationâ€based study. Pharmacoepidemiology and Drug Safety, 2017, 26, 1087-1092.	1.9	13
52	Loperamide abuse. Cmaj, 2017, 189, E803-E803.	2.0	6
53	The authors respond to "Inconsistencies in the 2017 Canadian Guideline for Opioids for Chronic Noncancer Pain― Cmaj, 2017, 189, E1234-E1235.	2.0	7
54	Maternal infection can cause spontaneous abortion. Cmaj, 2017, 189, E1021-E1021.	2.0	3

David N Juurlink

#	Article	IF	CITATIONS
55	Impact of Injectable Furosemide Hospital Shortage on Congestive Heart Failure Outcomes: A Time Series Analysis. Canadian Journal of Cardiology, 2017, 33, 1498-1504.	1.7	3
56	Medication use and kidney cancer risk: AÂpopulation-based study. European Journal of Cancer, 2017, 83, 203-210.	2.8	11
57	Association of a Blood Glucose Test Strip Quantity-Limit Policy With Patient Outcomes. JAMA Internal Medicine, 2017, 177, 61.	5.1	15
58	Diabetes and kidney cancer outcomes: a propensity score analysis. Endocrine, 2017, 55, 470-477.	2.3	8
59	Metformin Use and Kidney Cancer Outcomes in Patients With Diabetes: A Propensity Score Analysis. Clinical Genitourinary Cancer, 2017, 15, 300-305.	1.9	17
60	The Cardiovascular Safety of Dutasteride. Journal of Urology, 2017, 197, 1309-1314.	0.4	14
61	Availability of naloxone in Canadian pharmacies:a population-based survey. CMAJ Open, 2017, 5, E779-E784.	2.4	20
62	The value of complementing administrative data with abstracted information on smoking and obesity: A study in kidney cancer. Canadian Urological Association Journal, 2017, 11, 167.	0.6	6
63	Prior Authorization and Canadian Public Utilization of Direct-Acting Oral Anticoagulants. Healthcare Policy, 2017, 13, 68-78.	0.6	2
64	The Characteristics of Treated Pulmonary Arterial Hypertension Patients in Ontario. Canadian Respiratory Journal, 2016, 2016, 1-7.	1.6	4
65	The Influence of Socioeconomic Status on Selection of Anticoagulation for Atrial Fibrillation. PLoS ONE, 2016, 11, e0149142.	2.5	29
66	Off-label use of inhaled tobramycin in Ontario, Canada. Thorax, 2016, 71, 862-864.	5.6	1
67	Medication use and survival in diabetic patients with kidney cancer: A population-based cohort study. Pharmacological Research, 2016, 113, 468-474.	7.1	19
68	Statin use and kidney cancer outcomes: A propensity score analysis. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 487.e1-487.e6.	1.6	16
69	Who gets antidotes? choosing the chosen few. British Journal of Clinical Pharmacology, 2016, 81, 402-407.	2.4	13
70	Addressing the limitations of the CDC guideline for prescribing opioids for chronic noncancer pain. Cmaj, 2016, 188, 1210-1211.	2.0	27
71	Self-Monitoring of Blood Glucose Levels: Evaluating the Impact of a Policy of Quantity Limits on Test-Strip Use and Costs. Canadian Journal of Diabetes, 2016, 40, 431-435.	0.8	11
72	Bleeding associated with coadministration of rivaroxaban and clarithromycin. Cmaj, 2016, 188, 669-672.	2.0	26

#	Article	IF	CITATIONS
73	Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study. Canadian Journal of Cardiology, 2016, 32, 986.e17-986.e22.	1.7	21
74	Activated charcoal for acute overdose: a reappraisal. British Journal of Clinical Pharmacology, 2016, 81, 482-487.	2.4	89
75	Antiepileptic use for epilepsy and nonepilepsy disorders. Neurology, 2016, 86, 939-946.	1.1	29
76	The prescription opioid epidemic: an overview for anesthesiologists. Canadian Journal of Anaesthesia, 2016, 63, 61-68.	1.6	73
77	The Prescription Opioid Epidemic: Social Media Responses to the Residents' Perspective Article. Annals of Emergency Medicine, 2016, 67, 40-48.	0.6	7
78	Trends in the coprescription of proton pump inhibitors with clopidogrel: an ecological analysis. CMAJ Open, 2015, 3, E428-E431.	2.4	9
79	Rates of Ischemic Stroke During Warfarin Treatment for Atrial Fibrillation. Stroke, 2015, 46, 1120-1122.	2.0	9
80	Extracorporeal Treatment for Salicylate Poisoning: Systematic Review and Recommendations From the EXTRIP Workgroup. Annals of Emergency Medicine, 2015, 66, 165-181.	0.6	98
81	Neonatal opioid withdrawal and antenatal opioid prescribing. CMAJ Open, 2015, 3, E55-E61.	2.4	41
82	Rates of Anomalous Bupropion Prescriptions in Ontario, Canada. Annals of Family Medicine, 2015, 13, 343-346.	1.9	7
83	Trimethoprim–sulfamethoxazole and risk of sudden death among patients taking spironolactone. Cmaj, 2015, 187, E138-E143.	2.0	50
84	Tramadol and Hypoglycemia. JAMA Internal Medicine, 2015, 175, 194.	5.1	15
85	Long-term outcomes following self-poisoning in adolescents: a population-based cohort study. Lancet Psychiatry,the, 2015, 2, 532-539.	7.4	65
86	Proton pump inhibitors and the risk of acute kidney injury in older patients: a population-based cohort study. CMAJ Open, 2015, 3, E166-E171.	2.4	154
87	Risk of Suicide Following Deliberate Self-poisoning. JAMA Psychiatry, 2015, 72, 570.	11.0	146
88	Socioeconomic status and risk of hemorrhage during warfarin therapy for atrial fibrillation: A population-based study. American Heart Journal, 2015, 170, 133-140.e3.	2.7	28
89	Predictors of Opioid-Related Death During Methadone Therapy. Journal of Substance Abuse Treatment, 2015, 57, 30-35.	2.8	52
90	Sex Differences in Dose Escalation and Overdose Death during Chronic Opioid Therapy: A Population-Based Cohort Study. PLoS ONE, 2015, 10, e0134550.	2.5	124

#	Article	IF	CITATIONS
91	The Impact of Drug Reimbursement Policy on Rates of Testosterone Replacement Therapy among Older Men. PLoS ONE, 2014, 9, e98003.	2.5	28
92	Dextromethorphan abuse. Cmaj, 2014, 186, E631-E631.	2.0	15
93	Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ, The, 2014, 349, g6196-g6196.	6.0	84
94	Proton Pump Inhibitors and Hospitalization with Hypomagnesemia: A Population-Based Case-Control Study. PLoS Medicine, 2014, 11, e1001736.	8.4	60
95	Extended-release nifedipine and the risk of intestinal obstruction: a population-based study. BMJ Open, 2014, 4, e005377-e005377.	1.9	4
96	The Ontario Drug Policy Research Network: Bridging the gap between Research and Drug Policy. Health Policy, 2014, 117, 392-398.	3.0	15
97	Impact of legislation and a prescription monitoring program on the prevalence of potentially inappropriate prescriptions for monitored drugs in Ontario: a time series analysis. CMAJ Open, 2014, 2, E256-E261.	2.4	62
98	Unused prescription drugs should not be treated like leftovers. Cmaj, 2014, 186, 815-816.	2.0	17
99	The cardiovascular safety of azithromycin. Cmaj, 2014, 186, 1127-1128.	2.0	15
100	Risk of overdose and death following codeine prescription among immigrants. Journal of Epidemiology and Community Health, 2014, 68, 1057-1063.	3.7	7
101	Bupropion abuse and overdose. Cmaj, 2014, 186, 1015-1015.	2.0	36
102	Medicinal cannabis: Time to lighten up?. Cmaj, 2014, 186, 897-898.	2.0	6
103	Authors' reply to Scheper and Lijfering. BMJ, The, 2014, 349, g6906-g6906.	6.0	0
104	Adverse Cardiac Events in Older Patients Receiving Venlafaxine. Journal of Clinical Psychiatry, 2014, 75, e552-e558.	2.2	23
105	Trends in high-dose opioid prescribing in Canada. Canadian Family Physician, 2014, 60, 826-32.	0.4	85
106	Adherence to prescribing recommendations made on a provincial formulary. Healthcare Policy, 2014, 9, 20-30.	0.6	0
107	Improving Opioid Prescribing. JAMA - Journal of the American Medical Association, 2013, 309, 879.	7.4	32
108	Proton Pump Inhibitors and the Risk of Adverse Cardiac Events. PLoS ONE, 2013, 8, e84890.	2.5	32

#	Article	IF	CITATIONS
109	What the Internet can and cannot tell us about emerging toxicologic outbreaks. Clinical Toxicology, 2012, 50, 805-806.	1.9	1
110	Risk of Serious Falls Associated With Oxybutynin and Tolterodine: A Population Based Study. Journal of Urology, 2011, 186, 1340-1344.	0.4	36
111	Antidepressants, antiplatelets and bleeding: One more thing to worry about?. Cmaj, 2011, 183, 1819-1820.	2.0	4
112	Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ: British Medical Journal, 2009, 339, b2942-b2942.	2.3	150
113	Drug interactions with warfarin: what clinicians need to know. Cmaj, 2007, 177, 369-371.	2.0	81
114	Thiazolidinediones and Cardiovascular Outcomes in Older Patients With Diabetes. JAMA - Journal of the American Medical Association, 2007, 298, 2634.	7.4	303
115	Review: Nonselective nonsteroidal antiinflammatory drugs do not increase risk for cardiovascular events. ACP Journal Club, 2007, 146, 12.	0.1	2
116	Guillain-Barré Syndrome After Influenza Vaccination in Adults. Archives of Internal Medicine, 2006, 166, 2217.	3.8	172
117	A population-based assessment of the potential interaction between serotonin-specific reuptake inhibitors and digoxin. British Journal of Clinical Pharmacology, 2005, 59, 102-107.	2.4	28
118	Hyperbaric Oxygen for Carbon Monoxide Poisoning. Toxicological Reviews, 2005, 24, 159-160.	2.5	6
119	Drug-Induced Lithium Toxicity in the Elderly: A Population-Based Study. Journal of the American Geriatrics Society, 2004, 52, 794-798.	2.6	173
120	Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet, The, 2004, 363, 1751-1756.	13.7	418
121	ICES Report: Avoiding Drug Interactions in Hospitalized Patients. Healthcare Quarterly, 2004, 7, 27-28.	0.7	3
122	Drug-Drug Interactions Among Elderly Patients Hospitalized for Drug Toxicity. JAMA - Journal of the American Medical Association, 2003, 289, 1652.	7.4	605
123	Iron poisoning in young children: association with the birth of a sibling. Cmaj, 2003, 168, 1539-42.	2.0	2
124	Discrepant advice from poison centres and their medical directors. Canadian Journal of Clinical Pharmacology, 2002, 9, 101-5.	1.1	2